SEARCH

SEARCH BY CITATION

References

  • Axelrad, A.A., Eskinazi, D., Correa, P.N. & Amato, D. (2000) Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythaemia. Blood, 96, 33103321.
  • Barbui, T., Barosi, G., Grossi, A., Gugliotta, L., Liberato, L.N., Marchetti, M., Mazzucconi, M.G., Rodeghiero, F. & Tura, S. (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 89, 215232.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Elliott, M.A. & Tefferi, A. (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 128, 275290.
  • Fialkow, P.J., Faguet, G.B., Jacobson, R.J., Vaidya, K. & Murphy, S. (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood, 58, 916919.
  • Goerttler, P.S., Steimle, C., Marz, E., Johansson, P.L., Andreasson, B., Griesshammer, M., Gisslinger, H., Heimpel, H. & Pahl, H.L. (2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood First Edition Paper, prepublished online June 28, 2005; DOI 10.1182/blood-2005–04–1515.
  • Harrison, C.N. (2005) Essential thrombocythaemia: challenges and evidence-based management. British Journal of Haematology, 130, 153165.
  • Harrison, C.N., Gale, R.E., Pezella, F., Mire-Sluis, A., MacHin, S.J. & Linch, D.C. (1999a) Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. British Journal of Haematology, 107, 139147.
  • Harrison, C.N., Gale, R.E., Machin, S.J. & Linch, D.C. (1999b) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417424.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds) (2001) WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. IARC press, Lyon.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H.M. & Issa, J.P. (2005) JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood First Edition Paper, prepublished online July 21, 2005; DOI 10.1182/blood-2005–05–1800.
  • Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlman, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C.P. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood First Edition Paper, prepublished online May 26, 2005; DOI 10.1182/blood-2005–03–1320.
  • Juvonen, E., Ikkala, E., Oksanen, K. & Ruutu, T. (1993) Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. British Journal of Haematology, 83, 192197.
  • Koch, C.A., Lasho, T.L. & Tefferi, A. (2004) Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology, 127, 3439.
  • Kralovics, R., Passamonti, F., Buser, A.S., Soon-Siong, T., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 17791790.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Messinezy, M., Westwood, N.B., El-Hemaidi, I., Marsden, J.T., Sherwood, R.S. & Pearson, T.C. (2002) Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology, 117, 4753.
  • Michiels, J.J. & Thiele, J. (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). International Journal of Hematology, 76, 133145.
  • Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., Cazzola, M., Morra, E. & Lazzarino, M. (2004a) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 117, 755761.
  • Passamonti, F., Pietra, D., Malabarba, L., Rumi, E., Della, Porta, M.G., Malcovati, L., Bonfichi, M., Pascutto, C., Lazzarino, M. & Cazzola, M. (2004b) Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 126, 650656.
  • Reeder, T.L., Bailey, R.J., Dewald, G.W. & Tefferi, A. (2003) Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood, 101, 19811983.
  • Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. & Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood First Edition Paper, prepublished online April 28, 2005; DOI 10.1182/blood-2005–03–1183.
  • Tefferi, A., Fonseca, R., Pereira, D.L. & Hoagland, H.C. (2001) A long-term retrospective study of young women with essential thrombocythemia. Mayo Clinic Proceedings, 76, 2228.
  • Tefferi, A., Lasho, T.L., Wolanskyj, A.P. & Mesa, R.A. (2004a) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood, 103, 35473548.
  • Tefferi, A., Lasho, T.L., Brockman, S.R., Elliott, M.A., Dispenzieri, A. & Pardanani, A. (2004b) FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica, 89, 871873.
  • Tefferi, A., Lasho, T.L., Steensma, D.P., Mesa, R.A., Li, C.-Y., Wadleigh, M. & Gilliland, D.G. (2005a) The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology. in press.
  • Tefferi, A., Sirhan, S., Lasho, T.L., Schwager, S.M., Li, C.-Y., Dingli, D., Wolanskyj, A.P., Steensma, D.P., Mesa, R.A. & Gilliland, D.G. (2005b) Concomitant neutrophil JAK2 V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythemia. British Journal of Haematology. Online publication date, 6 September 2005, doi: 10.1111/j.1365–2141.2005.05743.x.
  • Yoon, S.Y., Li, C.Y. & Tefferi, A. (2000) Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. European Journal of Haematology, 65, 170174.
  • Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 2278822792.